MaryMulcahyMD

Oncology • Chicago, IL

Hematologic Oncology

Professor, Medicine, Northwestern University Medical School

Join to view full profile

Dr. Mulcahy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mulcahy's full profile

Already have an account?

Office
675 N Saint Clair St
Galter 21-100
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-1106

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
Boston University Medical CenterResidency, Internal Medicine, 1993 - 1996
University of California San Diego School of MedicineClass of 1993

Certifications & Licensure

IL State Medical License 1997 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Vaccine Treatment for Surgically Resected Pancreatic Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 1, Phase 2
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Start of enrollment: 2007 Feb 28
Completed
Phase 2
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Start of enrollment: 2008 Nov 07
Completed
Phase 2
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct Start of enrollment: 2008 Dec 01
Completed
Phase 2
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases Start of enrollment: 2009 Apr 01
Completed
Phase 1
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer Start of enrollment: 2010 Jan 18
Completed
Phase 2
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery Start of enrollment: 2009 Aug 01
Completed
Phase 2
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
Completed
Phase 2
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Start of enrollment: 2012 Jun 11
Completed
Phase 1
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Start of enrollment: 2012 Jan 01
Completed
Not Applicable
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2012 May 15
Active, not recruiting
Phase 2
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Start of enrollment: 2012 Dec 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

670 citations
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Joseph Chao, David Cooke
Journal of the National Comprehensive Cancer Network. 2022-02-01
309 citations
Rectal cancer, version 6.2020: Featured updates to the NCCN guidelines
Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi Jen Chen
Journal of the National Comprehensive Cancer Network. 2020-07-01
265 citations
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Al B Benson, Alan P Venook, Mahmoud M Al-Hawary, Nilofer Azad, Yi-Jen Chen
Journal of the National Comprehensive Cancer Network. 2022-10-01

Press Mentions

Microspheres Delay Progression of Colon CancerDecember 17th, 2021
Boston Scientific TheraSphere Improves Survival in mCRC PatientsSeptember 21st, 2021
Transarterial Radioembolization Slows Progression of CRC with Liver MetsSeptember 21st, 2021
Join now to see all